Cancer Screening, Assessment and Risk Evaluation and BRCA Colaris Testing of Genetic Predictors Offered in the Practice of Steven R. Poliakoff, M.D.
For any cancer there are different types of treatment modalities. One is obviously the physical examination. The second is blood tests, in which many tumors that make specific proteins are detected and measured hematologically, enabling diagnosis and evaluation of specific treatments.
Cancer Assessment Risk Evaluation Program® (C.A.R.E.)
For many women, having a family history of ovarian, breast, cervical or other cancer is a very emotional issue, especially when some of those family members have passed away from the disease. Dr. Poliakoff looks at a variety of factors to help those women who are at the greatest risk, educating them as to their risks and areas of concern, helping them to decide upon their options and putting the most advantageous action plan in place in the form of his cutting-edge Cancer Assessment Risk Evaluation Program® (C.A.R.E.).
Dr. Poliakoff has designed and refined the C.A.R.E. program over the years, enabling him to evaluate women who are at a high-risk of developing cancer, some of whom are from certain ethnic descent and may be carriers of certain types of cancers. Part of his protocol involves looking at familial history based upon prior cancers and current and past lifestyle, which allows him to screen women who may be at increased risk for developing breast, ovarian, or colon cancer. He then puts them on therapeutic intervention that prevents that development.
Many tumors make specific proteins that are measurable in the blood. These proteins, and the measurement of those in the bloodstream, enable Dr. Poliakoff to more accurately diagnosis and evaluate treatments, enabling speedy solutions when time is of the essence.
BRCAnalysis® Gene Testing
Dr. Poliakoff is at the forefront of cancer treatment, offering his patients BRCAnalysis® Gene Testing, which were created during research on the technological synthesis of the human genome for all cancers, which have given the medical community the information on thousands of switches that go on in the body. This allows for the recognition of specific points in the body's genes that make tumor suppressor cells, enabling a deeper understanding of the body's own immune system for preventing the development of cancer and the reason why some patients get cancer or are prone to cancer, due to the fact that they do not make these tumor suppressor cells.
BRACAnalysis is a genetic test that requires only a blood sample to determine whether a patient has a BRACA1 or BRCA2 gene mutation, indicating a predisposition to hereditary breast and ovarian cancer (HBOC). One in 500 women test positive for BRACA1 or BRCA2 gene mutations, and those patients have up to a 92 percent risk of developing breast or ovarian cancer or both, by age 70. If a patient has mutations in either of two breast cancer susceptibility genes - BRCA1 and BRCA2 - their risk of breast or ovarian cancer is significantly higher than that of a woman without such a mutation. How much higher depends on a number of other factors, including the woman's age and the ages at which women in their family developed breast or ovarian cancer. Mutation carriers previously diagnosed with cancer have a significantly increased risk of developing second cancers.
Who is at increased risk of having a mutated BRCA1 or BRCA2 gene?
Certain factors increase a patient's risk of having a BRCA mutation. They might be at increased risk of having a BRCA gene change if they have:
- A personal history of breast cancer diagnosed at a young age, breast cancer affecting both breasts (bilateral breast cancer), or both breast and ovarian cancers
- A family history of breast cancer in two or more close relatives, such as parents, siblings and children
- A family member who developed breast cancer before age 50 on either the mother's or father's side of the family
- A family history of breast cancer in more than one generation
- A male relative with breast cancer
- A family member who has both breast and ovarian cancers
- A family member with bilateral breast cancer
- A frequent occurrence of ovarian cancer within the patient's family
- A positive BRCA1 or BRCA2 genetic test in a relative
- Ashkenazi (Eastern European) Jewish ancestry, with or without a family history of breast or ovarian cancer
Researchers have discovered that 2.3 percent of women of Ashkenazi descent carry a BRCA mutation - about five times greater than that of the general population.
Results of the BRCA tests provide Dr. Poliakoff with critical information that enables him to recognize if a patient is deficient in a signal that turns on an area of the body that makes cells that kill cancer, enabling him to give the patient back that signal by synthesizing the gene, attaching the gene to the common cold virus and giving them the virus. Understanding where cells go abnormal, why they're abnormal and how they're acting abnormally enables him to save lives.
COLARIS® Gene Testing
Dr. Poliakoff's patients who are at risk for colorectal cancers associated with hereditary nonpolyposis colorectal cancer (HNPCC) can be tested utilizing COLARIS Gene Testing, allowing for early detection and prevention. Research has shown that females with HNPCC have up to a 71 percent risk of developing endometrial cancer by age 70. All patients with HNPCC are at increased risk for other cancers as well, including cancers of the ovary, stomach, ureter/renal pelvis, biliary tract, small bowel, pancreas, brain and sebaceous adenomas.
The patient's personal and family medical history can reveal that a predisposition to the disease exists. When assessing hereditary cancer risk, a patient's comprehensive family history remains an essential part in determining if there is a possibility of HNPCC. However, genetic testing is the most accurate way to diagnose patients with HNPCC.